Inhibitory effects of NFκB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model

Journal of Molecular and Cellular Cardiology

Volumn 41, Issue 3, 2006, Pages 431-440

  Miyake, Takashi ^a,b   Aoki, Motokuni ^a   Shiraya, Suguru ^a   Tanemoto, Kazuo ^b   Ogihara, Toshio ^a   Kaneda, Yasufumi ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Decoy; Endothelial cell; Gene therapy; Graft failure; NF B

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OLIGONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY GRAFT; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; CAROTID ARTERY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; DRUG SYNTHESIS; GENETIC TRANSFECTION; HYPERCHOLESTEROLEMIA; JUGULAR VEIN; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; VASCULAR SMOOTH MUSCLE; VEIN GRAFT; ANIMAL; CHEMISTRY; CYTOLOGY; ENDOTHELIUM CELL; GENETICS; GRAFT OCCLUSION; HYPERPLASIA; INTIMA; METABOLISM; PATHOLOGY; STENOSIS, OCCLUSION AND OBSTRUCTION; TRANSPLANTATION; VASCULAR ENDOTHELIUM; VEIN;

ORYCTOLAGUS CUNICULUS;

ANIMALS; CAROTID ARTERIES; CONSTRICTION, PATHOLOGIC; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GRAFT OCCLUSION, VASCULAR; HYPERPLASIA; JUGULAR VEINS; MALE; NF-KAPPA B; OLIGONUCLEOTIDES; RABBITS; TRANSPLANTS; TUNICA INTIMA; VEINS;

EID: 33748415182     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.04.006     Document Type: Article

References (43)

1. Motwani J.G., and Topol E.J. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97 (1998) 916-931
2. Fitzgibbon G.M., Kafka H.P., Leach A.J., Keon W.J., Hooper G.D., and Burton J.R. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5065 grafts related to survival and reoperation in 1388 patients during 25 years. J Am Coll Cardiol 28 (1996) 616-626
3. Sasaki Y., Suehiro S., Becker A.E., Kinoshita H., and Ueda M. Role of endothelial cell denudation and smooth muscle cell dedifferentiation in neointimal formation of human vein grafts after coronary artery bypass grafting: therapeutic implications. Heart 83 (2000) 69-75
4. Shi Y., O'Brien Jr. J.E., Mannion J.D., Morrison R.C., Chung W., Fard A., et al. Remodeling of autologous saphenous vein grafts. The role of perivascular myofibroblasts. Circulation 95 (1997) 2684-2693
5. Moreno P.R., Bernardi V.H., Lopez-Cuellar J., Newell J.B., McMellon C., Gold H.K., et al. Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Circulation 94 (1996) 3098-3102
6. Jawien A., Bowen-Pope D.F., Lindner V., Schwartz S.M., and Clowes A.W. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 89 (1992) 507-511
7. Feldman L.J., Aguirre L., Ziol M., Bridou J.P., Nevo N., Michel J.B., et al. Interleukin-10 inhibits intimal hyperplasia after angioplasty or stent implantation in hypercholesterolemic rabbits. Circulation 101 (2000) 908-916
8. Bourcier T., Sukhova G., and Libby P. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 272 (1997) 15817-15824
9. Brand K., Page S., Rogler G., Bartsch A., Brandl R., Knuechel R., et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 97 (1996) 1715-1722
10. Selzman C.H., Shames B.D., Reznikov L.L., Miller S.A., Meng X., Barton H.A., et al. Liposomal delivery of purified inhibitory-kappaBalpha inhibits tumor necrosis factor-alpha-induced human vascular smooth muscle proliferation. Circ Res 84 (1999) 867-875
11. Erl W., Hansson G.K., de Martin R., Draude G., Weber K.S., and Weber C. Nuclear actor-kappa B regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells. Circ Res 84 (1999) 668-677
12. Weber C., Erl W., Pietsch A., and Weber P.C. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 91 (1995) 1914-1917
13. Ledebur H.C., and Parks T.P. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers. J Biol Chem 270 (1995) 933-943
14. Yoshimura S., Morishita R., Hayashi K., Yamamoto K., Nakagami H., Kaneda Y., et al. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy. Gene Ther 8 (2001) 1635-1642
15. Yamasaki K., Asai T., Shimizu M., Aoki M., Hashiya N., Sakonjo H., et al. Inhibition of NFkappaB activation using cis-element 'decoy' of NFkappaB binding site reduces neointimal formation in porcine balloon-injured coronary artery model. Gene Ther 10 (2003) 356-364
16. Mann M.J., Gibbons G.H., Hutchinson H., Poston R.S., Hoyt E.G., Robbins R.C., et al. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci U S A 96 (1999) 6411-6416
17. Aoki M., Morishita R., Higaki J., Moriguchi A., Hayashi S., Matsushita H., et al. Survival of grafts of genetically modified cardiac myocytes transfected with FITC-labeled oligodeoxynucleotides and the beta-galactosidase gene in the noninfarcted area, but not the myocardial infarcted area. Gene Ther 4 (1997) 120-127
18. Simons M., Edelman E.R., DeKeyser J.L., Langer R., and Rosenberg R.D. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359 (1992) 67-70
19. Morishita R., Gibbons G.H., Ellison K.E., Nakajima M., Zhang L., Kaneda Y., et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A 90 (1993) 8474-8478
20. Yamamoto K., Morishita R., Tomita N., Shimozato T., Nakagami H., Kikuchi A., et al. Ribozyme oligonucleotides against transforming growth factor-beta inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease. Circulation 102 (2000) 1308-1314
21. Bielinska A., Shivdasani R.A., Zhang L.Q., and Nabel G.J. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 250 (1990) 997-1000
22. Morishita R., Gibbons G.H., Horiuchi M., Ellison K.E., Nakama M., Zhang L., et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A 92 (1995) 5855-5859
23. Mann M.J., Whittemore A.D., Donaldson M.C., Belkin M., Conte M.S., Polak J.F., et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 354 (1999) 1493-1498
24. Parhami F., Fang Z.T., Fogelman A.M., Andalibi A., Territo M.C., and Berliner J.A. Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. J Clin Invest 92 (1993) 471-478
25. Dichtl W., Nilsson L., Goncalves I., Ares M.P., Banfi C., Calara F., et al. Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. Circ Res 84 (1999) 1085-1094
26. Jawien J., Gajda M., Mateuszuk L., Olszanecki R., Jakubowski A., Szlachcic A., et al. Inhibition of nuclear factor-kappaB attenuates artherosclerosis in apoE/LDLR- double knockout mice. J Physiol Pharmacol 56 (2005) 483-489
27. Kuang P.P., Berk J.L., Rishikof D.C., Foster J.A., Humphries D.E., Ricupero D.A., et al. NF-kappaB induced by IL-1beta inhibits elastin transcription and myofibroblast phenotype. Am J Physiol, Cell Physiol 283 (2002) 58-65
28. Kahari V.M., Chen Y.Q., Bashir M.M., Rosenbloom J., and Uitto J. Tumor necrosis factor-alpha down-regulates human elastin gene expression. Evidence for the role of AP-1 in the suppression of promoter activity. J Biol Chem 267 (1992) 26134-26141
29. Zou Y., Hu Y., Mayr M., Dietrich H., Wick G., and Xu Q. Reduced neointima hyperplasia of vein bypass grafts in intercellular adhesion molecule-1-deficient mice. Circ Res 86 (2000) 434-440
30. Stark V.K., Hoch J.R., Warner T.F., and Hullett D.A. Monocyte chemotactic protein-1 expression is associated with the development of vein graft intimal hyperplasia. Arterioscler Thromb Vasc Biol 17 (1997) 1614-1621
31. Tomita N., Morishita R., Tomita S., Yamamoto K., Aoki M., Matsushita H., et al. Transcription factor decoy for nuclear factor-kappaB inhibits tumor necrosis factor-alpha-induced expression of interleukin-6 and intracellular adhesion molecule-1 in endothelial cells. J Hypertens 16 (1998) 993-1000
32. Schwartz S.M. Perspectives series: cell adhesion in vascular biology. Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 99 (1997) 2814-2816
33. George S.J., Zaltsman A.B., and Newby A.C. Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. Cardiovasc Res 33 (1997) 447-459
34. Mavromatis K., Fukai T., Tate M., Chesler N., Ku D.N., and Galis Z.S. Early effects of arterial hemodynamic conditions on human saphenous veins perfused ex vivo. Arterioscler Thromb Vasc Biol 20 (2000) 1889-1895
35. Pauly R.R., Passaniti A., Bilato C., Monticone R., Cheng L., Papadopoulos N., et al. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res 75 (1994) 41-54
36. George S.J., Lloyd C.T., Angelini G.D., Newby A.C., and Baker A.H. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 101 (2000) 296-304
37. Bond M., Baker A.H., and Newby A.C. Nuclear factor kappaB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun 264 (1999) 561-567
38. Takeshita H., Yoshizaki T., Miller W.E., Sato H., Furukawa M., Pagano J.S., et al. Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J Virol 73 (1999) 5548-5555
39. Kim H., and Koh G. Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF-kappaB-dependent pathway. Biochem Biophys Res Commun 269 (2000) 401-405
40. Bossaller C., Habib G.B., Yamamoto H., Williams C., Wells S., and Henry P.D. Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J Clin Invest 79 (1987) 170-174
41. Davies M.G., and Hagen P.O. Pathophysiology of vein graft failure. Eur J Vasc Endovasc Surg 9 (1995) 7-18
42. Ku D.D., Caulfield J.B., and Kirklin J.K. Endothelium-dependent responses in long-term human coronary artery bypass grafts. Circulation 83 (1991) 402-411
43. Matsushita H., Morishita R., Nata T., Aoki M., Nakagami H., Taniyama Y., et al. Hypoxia-induced endothelial apoptosis through nuclear factor-kappaB (NF-kappaB)-mediated bcl-2 suppression: in vivo evidence of the importance of NF-kappaB in endothelial cell regulation. Circ Res 86 (2000) 974-981